Jan 10, 2020

Hogan Lovells advised Altavant Sciences in its acquisition of Onspira Therapeutics. This acquisition expanded Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with US FDA orphan drug designation. OSP-101 is in development for the treatment of bronchiolitis obliterans syndrome (BOS), the leading cause of morbidity and mortality in post-lung transplant patients. Onspira Therapeutics is a private drug development company similarly focused on therapeutics for rare pulmonary diseases. Altavant Sciences is a clinical-stage biopharmaceutical company formed to advance promising therapies that treat rare respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension.